NR3C2 and myocardial infarction: These include early reperfusion therapy forST-segment elevation myocardial infarction (STEMI), early application ofangiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers(ARB) and mineralocorticoid receptor antagonists (MRA), routine administration ofhigh-dose statins, and early evaluation of the indications for β-blockersduring and after a myocardial infarction [23].